MTPConnect is Australia's Life Sciences Innovation Accelerator – an independent, not-for-profit organisation established by the Australian Government to champion the continuing growth of Australia's vibrant medical products sector.
MTPConnect’s focus is taking cutting-edge research from bench to bedside by working collaboratively with all parts of Australia’s medical technology, biotechnology and pharmaceutical sector; from universities and medical research institutes to start-ups and small to medium sized enterprises to listed companies, and governments, policy makers and regulators.
MTPConnect designs and delivers accelerator, sector building and workforce programs for Australian Government agencies and state governments. It co-funds cutting edge innovation and research projects, supports expansion of the clinical trials ecosystem, develops workforce commercialisation skills and represents the Australian sector with a strong and independent voice to promote connections to international markets and improve access to global supply chains.
MTPConnect operates the industry-led Australian Antimicrobial Resistance Network – AAMRNet – a collaborative network of key stakeholders working together to address the impact of AMR on human health. It seeks to create an accelerator that will back Australian research into new antimicrobial innovations and to secure investment for a pilot subscription fund for novel antimicrobials to ensure Australians have equitable access to the latest life-saving antibiotics. It also has a dedicated Health and Biosecurity team driving development of dual purpose, advanced medical countermeasures and Defence/National Security related technologies.
Across MTPConnect’s accelerator programs, more than $152 million has been directly injected into the Australian life sciences sector, supporting nearly 200 innovation projects. Its investments have leveraged more than $1.3 billion in additional industry contributions and flow-on external investment, allowing SMEs to scale-up and create new jobs and new medical products.
MTPConnect’s work has seen more than 1,696 new technologies invented or progressed, 374 new products launched and over 746,000 patients treated.
